#BCLI

Zacks Small Cap Research

@zackssmallcap.bsky.social

7 months ago

#BCLI: Focused on Initiation of Phase 3b ENDURANCE Trial of NurOwn® in ALS… buff.ly/KLychw1

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update BrainStorm Cell Therapeutics (OTCQB: BCLI), a developer of adult stem cell therapeutics for neurodegenerative diseases, will host its Q2 2025 financial results conference call on August 14, 2025, at 8:30 AM ET.The call will feature presentations from key executives including CEO Chaim Lebovits, COO Hartoun Hartounian, CMO Bob Dagher, and Interim CFO Alla Patlis, followed by a Q&A session. Investors can submit questions in advance to q@brainstorm-cell.com by August 12, 2025, at 10:00 AM ET.

#BCLI BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

www.stocktitan.net/news/BCLI/brain-storm-to...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

7 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Thu Jul 17th - #NEXM #CEPO #PDSB #NB #KLRS #GAME #CDNA #BCLI #OPAD #EB - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

BrainStorm Cell Faces Nasdaq Exit: What the OTCQB Switch Means for Investors and NurOwn Program BrainStorm Cell transitions to OTCQB after Nasdaq delisting. CEO confirms NurOwn development continues with FDA-approved Phase 3b trial plans. Get insights.

#BCLI BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB

www.stocktitan.net/news/BCLI/brain-storm-ce...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

NurOwn ALS Treatment Gets Fresh FDA Review as Breakthrough 6.8-Year Survival Data Emerges FDA examines new evidence for NurOwn ALS therapy showing 5+ year survival rates. Phase 3b trial proceeds while fresh survival data reveals promising outcomes. Learn more.

#BCLI FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness

www.stocktitan.net/news/BCLI/fda-review-of-...

0 0 0 0

Zacks Small Cap Research

@zackssmallcap.bsky.social

8 months ago

#BCLI: Citizen’s Petition Filed Requesting the FDA Approve NurOwn™… buff.ly/awOwHhN

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

8 months ago

Female doctor examining brain scans on multiple digital monitors in a modern medical facility.

#BCLI jumps after BrainStorm reports 90% of ALS patients in its Expanded Access Program survived over 5 years on NurOwn. New data boosts confidence ahead of Phase 3b trial.
#BrainstormCell
prismmarketview.com/brainstorm-s...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Revolutionary ALS Treatment Shows 90% Patient Survival vs Traditional 10% Rate - NurOwn's Game-Changing Results New data reveals unprecedented survival rates in ALS patients. Discover how NurOwn therapy achieved 90% survival beyond 5 years versus typical 10% rate. See full results.

#BCLI BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®

www.stocktitan.net/news/BCLI/brain-storm-an...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

BrainStorm Accelerates NurOwn ALS Treatment Development Through Major Manufacturing Deal with Minaris BrainStorm expands US manufacturing capabilities for NurOwn ALS therapy through strategic Minaris partnership. Learn how this advances Phase 3b trial preparations. Get details.

#BCLI #PLUR BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

www.stocktitan.net/news/BCLI/brain-storm-se...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Mon May 19th - #NLSP #MDB #MDCX #ENVB #DVLT #TNGX #QMCO #NVAX #LAES #KTCC #INV #GAN #FTEK #FENC #CXAI #BCLI #AGAE #SOC #PGRE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS Investor call and webcast scheduled for today at 8:30 a.m. ET. NEW YORK, May 19, 2025/ PRNewswire/-- BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration has cleared the company to initiate its Phase 3 b clinical trial of NurOwn ® for the...

#BCLI BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

www.stocktitan.net/news/BCLI/brain-storm-re...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

BrainStorm's NurOwn ALS Treatment Takes Major Step Forward: FDA Amendment Filed, Trial Sites Ready Latest FDA submission paves way for 200-patient Phase 3b trial of NurOwn ALS treatment. See financial results and breakthrough scientific data presented at ISCT 2025.

#BCLI BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BCLI/brain-storm-ce...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 BrainStorm Cell Therapeutics (NASDAQ: BCLI), a developer of adult stem cell therapeutics for neurodegenerative diseases, has scheduled its Q1 2025 financial results conference call for May 15, 2025, at 8:30 a.m. Eastern Time. The call will feature CEO Chaim Lebovits presenting a corporate update, joined by CMO Bob Dagher and Interim CFO Alla Patlis for a Q&A session.Shareholders can submit questions in advance to q@brainstorm-cell.com by May 12, 2025, at 5:00 p.m. ET. The call will be accessible via toll-free (888-506-0062) and international (973-528-0011) numbers, with participant code 621608. A replay will be available for 14 days.

#BCLI BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025

www.stocktitan.net/news/BCLI/brain-storm-ce...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Groundbreaking ALS Treatment Discovery: How Genetics May Predict NurOwn Therapy Success New pharmacogenomic findings reveal UNC13A genotype's impact on ALS treatment outcomes. First-of-its-kind analysis advances personalized medicine. See breakthrough data.

#BCLI BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting

www.stocktitan.net/news/BCLI/brain-storm-s-...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Major FDA Progress: New Phase 3b Trial Brings NurOwn ALS Treatment Closer to Approval FDA-aligned trial design targets 200 ALS patients with innovative stem cell therapy. Special Protocol Assessment guides path to potential approval. See trial details inside.

#BCLI BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS

www.stocktitan.net/news/BCLI/brain-storm-ce...

0 0 0 0

ORTEX

@ortex.com

11 months ago

HeatMaps - ORTEX

📢 Earnings Are In!

This morning’s earnings lineup includes #BCLI, #BLRX, #FTCI, #NNOX, #WKHS, and others.

Track the impact on the market with our Earnings Heat Map:
app.ortex.com/earnings/hea...

#Earnings #Markets #Investing

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

BrainStorm Cell Slashes Losses by 33%, Secures FDA Agreement for Major ALS Trial Net loss reduced to $11.6M as BrainStorm advances Phase 3b ALS trial preparations. New Pluri partnership and patent strengthen strategic position. See financial details.

#BCLI BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BCLI/brain-storm-ce...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

11 months ago

BrainStorm Cell Therapeutics Receives Nasdaq Compliance Extension Until June 2025 BrainStorm Cell Therapeutics has secured an extension from Nasdaq to meet compliance standards. The company aims to enhance its financial position while advancing its therapies for neurodegenerative diseases.

BrainStorm Cell Therapeutics Receives Nasdaq Compliance Extension Until June 2025 #United_States #New_York #BrainStorm #BCLI #NurOwn

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

BrainStorm Wins Critical Nasdaq Extension: New ALS Study and Strategic Plans Unveiled Nasdaq grants BrainStorm 16-month compliance extension as company launches Phase 3b ALS study and pursues strategic partnerships. Full turnaround plan inside.

#BCLI BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq

www.stocktitan.net/news/BCLI/brain-storm-ce...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

BrainStorm Cell Therapeutics Sets Major Investor Briefing: CEO, COO, and CMO to Reveal 2024 Performance Key executives to present comprehensive corporate strategy alongside Q4 results. Submit questions by March 28. Full management analysis and future outlook inside.

#BCLI BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update

www.stocktitan.net/news/BCLI/brain-storm-to...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

BrainStorm Cell Advances NurOwn ALS Treatment with FDA Special Protocol Assessment and Manufacturing Deal BrainStorm Cell Therapeutics secures FDA Special Protocol Assessment for NurOwn Phase 3b trial in ALS, partners with Pluri for manufacturing, and advances biomarker research.

#BCLI BrainStorm Issues 2024 Letter to Shareholders

www.stocktitan.net/news/BCLI/brain-storm-is...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

BrainStorm Cell Therapeutics Expands Its Patent Portfolio for Exosome Technology BrainStorm Cell Therapeutics has been granted a Notice of Allowance for a U.S. patent covering its groundbreaking exosome technology, enhancing its intellectual property.

BrainStorm Cell Therapeutics Expands Its Patent Portfolio for Exosome Technology #USA #New_York #BrainStorm #exosome_technology #BCLI

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

BrainStorm Cell Therapeutics Secures Key Patent for Breakthrough Exosome Technology | BCLI Stock News BrainStorm Cell Therapeutics receives USPTO patent protection until 2039 for its innovative MSC-NTF cell exosome technology, strengthening its position in neurotrophic therapies.

#BCLI BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology

#news #StockMarket #stocks

www.stocktitan.net/news/BCLI/brain-storm-st...

0 0 0 0

Janice Barclay / proudscotJB

@janiceb.bsky.social

1 year ago

Thank you so much Joe 🥰. I love this #BCLI community 💖 and I’m so glad we’ve managed to recreate it here on the Blue side 🦋

0 0 0 0

Kιƚƚყ ₜₕₑ ᵥₑgₐₙ ₛₒcᵢₐₗᵢₛₜ 📎Ⓥ🌱💚🦇🌍🐠🇬🇧🇪🇺

@sparklykitten.bsky.social

1 year ago

a stuffed animal with big eyes and the word netflix on the bottom ALT: a stuffed animal with big eyes and the word netflix on the bottom

Fabulous, thanks my darling Joe. Managed to catch a few I wasn't already following too. Happy #Caturday and have a fabulous #BCLI 🥰😘

1 0 0 0

TeeDixie ✊🏼 #Resist

@teedixie.bsky.social

1 year ago

a man in a black shirt is making a peace sign with his hands in a living room . ALT: a man in a black shirt is making a peace sign with his hands in a living room .

Yayyyyyyyy he’s BACK!

#BCLI BlueSky Community Love In new edition!

1 0 0 0

Joe Hardy

@blokeonwheels.bsky.social

1 year ago

Lovely people let's try this again! The #BigCommunityLoveIn Bluesky edition! If you're not here, it's probably because I couldn't find your handle! It's definitely not because I don't think you're awesome. Anyway, here we go mostly no particular order! If you know you know. #BCLI

254 56 34 1